Xlife Sciences AG
Xlife Sciences AG is a Swiss investment holding company that sources early-stage life sciences research from universities and research institutions, incubates 19 portfolio companies across technology platforms, therapeutics, medical technology, and AI, and realizes value through trade sales, licensing, and IPOs.
- Company typePublic
- Founded2019
- HeadquartersZürich, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Xlife Sciences AG does
Xlife Sciences AG is a Swiss investment holding company founded in 2019 and headquartered in Zurich, listed on the Main Segment of the SIX Swiss Exchange (ticker XLS). The company operates a structured incubation platform that sources early-stage life sciences innovations from universities, clinical centers, and research institutions, reviewing approximately 300 invention disclosures per year and forming 1-2 new project companies annually with roughly CHF 1.5 million of financing per project (plus up to CHF 500k in potential grants). Its portfolio of 19 companies spans four segments: Technology Platforms (53% of portfolio value, including VERAXA Biotech's BiTAC bispecific T-cell engager and ADC oncology platform), Biotechnologies/Therapeutics (38%, including Baliopharm's Atrosimab TNFR1 antibody and Lysatpharma's exosome therapies), Medical Technology (6%, including saniva diagnostics' NeuroMex Alzheimer's detection device with FDA clearance and MDR certification), and Artificial Intelligence (3%, primarily FUSE-AI's ProstateCarcinoma.ai radiology software with EU MDR Class IIa registration). The company develops portfolio companies to proof-of-concept and realizes value through trade sales, out-licensing, and IPOs — the VERAXA Biotech NASDAQ listing in June 2026 at >USD 500 million market cap being the most significant exit to date. Reported operating revenue is minimal by design (CHF 0.28 million in 2025, CHF 0.83 million in 2024), with total assets of CHF 517.1 million and equity of CHF 372.4 million as of 2025 reflecting the portfolio NAV rather than operating scale.
Xlife Sciences AG firmographics
Firmographics- Name
- Xlife Sciences AG
- Legal name
- Xlife Sciences AG
- Website
- https://xlifesciences.ch
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Xlife Sciences AG is a Swiss investment holding company that sources early-stage life sciences research from universities and research institutions, incubates 19 portfolio companies across technology platforms, therapeutics, medical technology, and AI, and realizes value through trade sales, licensing, and IPOs.
- Ownership category
- akta.pro rank
Xlife Sciences AG industry classification
Industry- Product category
- Life Sciences Investment & Incubation
- NAICS
- Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282), Services-Management Consulting Services (8742)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Xlife Sciences AG is headquartered
LocationHeadquarters
- HQ city
- Zürich
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Xlife Sciences AG business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Portfolio Company Exits: Xlife Sciences generates returns through exit strategies including trade sales (selling portfolio companies to larger pharmaceutical or healthcare players), out-licensing of patents and technologies, and IPOs of portfolio companies on public markets. Exits typically occur within 2-3 years after proof-of-concept.
- Portfolio Company Services: The company provides comprehensive support to portfolio companies including business development, marketing, HR, structuring, and research support, funded through equity stakes in portfolio companies.
- Revenue from Portfolio Operations: Reported revenue of CHF 0.28 million in 2025 and CHF 0.83 million in 2024, likely from management fees, milestone payments, or operational contributions from portfolio companies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Xlife Sciences AG product offering
Product offeringCore offering
Xlife Sciences AG operates as a Swiss life sciences investment holding company that identifies, develops, and commercializes early-stage research projects sourced from universities and research institutions. The company builds and manages a portfolio of companies across four segments (Technology Platforms, Biotechnologies/Therapeutics, Medical Technology, and Artificial Intelligence) from inception through proof-of-concept, exiting via trade sales, licensing, or IPOs. VERAXA Biotech's NASDAQ listing in June 2026, with a market capitalization exceeding USD 500 million, exemplifies the platform's incubation-to-exit model.
Product overview
Xlife Sciences AG operates as a Swiss life sciences investment holding company that develops and commercializes early-stage research projects from universities and research institutions. Rather than offering a single unified product, Xlife functions as an incubator and investment platform across four distinct business segments: Technology Platforms (53% of portfolio, including VERAXA Biotech with its BiTAC/ADC cancer therapy platform, Inflamed Pharma with ProcCluster and DAZAmed products), Biotechnology/Therapeutics (38%, including Baliopharm's Atrosimab, Lysatpharma's exosome therapies, and various oncology candidates), Medical Technology (6%, including NeuroMex Alzheimer's detection device, Axenoll's 3D bioprinting), and Artificial Intelligence (3%, including FUSE-AI's radiology AI software). The company supports portfolio companies through proof-of-concept phases and commercializes through trade sales, licensing, or public listings. VERAXA Biotech's successful NASDAQ IPO in June 2026 demonstrated the effectiveness of this model.
Differentiator
Problem solved
Functional benefit
Products and services
- VERAXA Biotech Clinical-stage biopharmaceutical company spun out from EMBL, developing next-generation antibody-based cancer therapies using its proprietary BiTAC (Bispecific T-cell Attacking Construct) platform and antibody-drug conjugate (ADC) technologies for solid tumor treatment.
- FUSE-AI E-health company developing AI-supported software solutions for radiology, including ProstateCarcinoma.ai which achieved EU MDR Class IIa registration for automated prostate cancer detection from medical images.
- NeuroMex Medical device developed by saniva diagnostics for early detection of neurodegenerative diseases such as Alzheimer's and Parkinson's disease using motor responsiveness recordings; received FDA clearance and MDR certification, demonstrating 83.5% accuracy in identifying early-stage Alzheimer's.
- ProcCluster Advanced pharmaceutical compound developed by Inflamed Pharma for the treatment of inflammatory pain conditions, improving pharmaceutical compounds with poor solubility.
- DAZAmed Liver-specific PET tracer (radio-pharmaceutical) for hepatobiliary diagnostics developed by x-nuclear diagnostics, marking a breakthrough in liver diagnostics.
- Atrosimab Novel TNFR1 receptor antagonist antibody developed by Baliopharm for treating acute and chronic inflammatory diseases, which successfully completed Phase I clinical trials in April 2022.
- palleos healthcare CRO Services Full-service Contract Research Organization (CRO) offering clinical research services from clinical development to trial completion, serving both internal portfolio companies and external clients.
- Axenoll 3D Bioprinting 3D printing of biomaterials for applications in the medical and biotechnology sectors, having received a strategically significant patent from the European Patent Office.
Quantifiable outcome
- 83.5% accuracy in early Alzheimer's detection
- +2 more outcomes
Companies that use Xlife Sciences AG
Customer profileSegments2 records
Ideal customer profiles3 records
Xlife Sciences AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
Xlife Sciences AG partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Huraypositive Corp. and OncoMASTER Inc.coreStrategic collaboration to boost digital health and precision oncology in Asia. Combines Xlife Sciences' portfolio companies with Asian partners for market expansion and technology adoption in the region.
- JIPYONG LLC and JIPYONG IPcoreStrategic alliance to accelerate Korean life sciences ventures' access to global capital markets. JIPYONG provides advisory and capital markets expertise for Korean market access.
- HovionecoreStrategic collaboration between portfolio company Firstgene Life Sciences and Hovione in the field of gene therapy. Hovione provides manufacturing and development capabilities for gene therapy products.
- OCT Clinical GmbHminorStrategic merger between palleos healthcare GmbH and OCT Clinical GmbH, combining clinical research services expertise.
- Department of Health Abu Dhabi, Thermo Fisher Scientific, and Masdar CitycoreCollaboration expanded with Department of Health Abu Dhabi, partnering with Thermo Fisher Scientific and Masdar City to drive global innovations in the life sciences sector.
- Department of Health Abu DhabicoreCollaboration with Department of Health Abu Dhabi to drive global innovations in the life sciences sector.
- University of Mainz and Thoraxklinik Heidelbergminorxprot project company signed cooperation agreement with University of Mainz and Thoraxklinik Heidelberg.
- University of MarburgminorCollaboration with University of Marburg for the development of genetic-based therapeutic approaches.
- IndivumedminorJoint venture with Indivumed for cancer research and personalized medicine development.
- Anfass Life Technologies AGminorJoint venture QUADIRA BIOSCIENCES AG between Anfass Life Technologies AG and Xlife Sciences AG for improvement of antibody-drug conjugates.
- Curasan AGminorJoint venture Novaxomx GmbH (between Curasan AG and Xlife Sciences AG) for research and development of exosomes for musculoskeletal diseases.
- European Molecular Biology Laboratory (EMBL)coreVERAXA Biotech is a spin-off from EMBL in Heidelberg, developing antibody-based cancer therapies using innovative technologies from EMBL research.
- Philipps University MarburgminorInventum Genetics works with the Centre for Human Genetics at Philipps University in Marburg, Germany, for identifying therapeutic approaches based on human genetic data.
Scale indicators17 records
Recent moves12 records
Expansion highlights6 records
Xlife Sciences AG competitors and assessment
Company assessmentDirect peers
- PureTech Health: UK-listed (LSE) company that founds, incubates, and develops therapeutic and technology platform companies from academic research, with a similar hub-and-spoke model of multiple operating subsidiaries and regular public-market or M&A exits.
- BB Biotech AG: Swiss-listed investment holding focused on publicly traded biotech equities; comparable as a Zurich-based, listed vehicle offering investors liquid exposure to a diversified biotech portfolio with active portfolio management.
- HBM Healthcare Investments: Swiss investment company listed on SIX that invests across the healthcare value chain from early-stage private companies to listed pharma, providing a directly comparable publicly traded healthcare holding structure.
- TVM Capital Life Sciences: Life-sciences-focused venture capital firm that invests in early- and late-stage therapeutics and medical technology companies, mirroring Xlife Sciences' preclinical-to-proof-of-concept incubation model.
- EQT Life Sciences (formerly LSP): European life sciences investor under EQT, financing innovative life sciences companies from early-stage through growth; comparable as a pan-European institutional life sciences investor with similar exit horizons.
- Vesalius Biocapital: European venture capital firm specialized in early- to mid-stage life sciences investments, comparable to Xlife Sciences in its focus on European academic spinouts and platform technologies.
Broad incumbents
- Index Ventures (Life Sciences): Major global venture capital firm with a dedicated life sciences practice investing across therapeutics, medtech, and digital health; comparable as a broader incumbent in European life sciences venture funding.
- OrbiMed Advisors: Global healthcare-dedicated investment firm covering venture, growth, and public equities across biopharma, medtech, and diagnostics; a broader incumbent operating across the same life sciences verticals.
Emerging players
- Roche Venture Fund: Corporate venture arm of Roche investing in early-stage life sciences companies; comparable as a corporate-backed investor taking meaningful minority stakes in emerging biotech and platform technologies.
- Novartis Venture Fund: Corporate venture arm of Novartis focused on early-stage life sciences investments, providing a peer in the CVC channel that funds therapeutic platforms often spun out of academic research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Xlife Sciences AG social profiles
Digital presenceXlife Sciences AG compliance and trust
Trust signalCompliance3 records
Xlife Sciences AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xlife Sciences AG leadership team
Management profileNumber of profiles
Profiles7 records
Xlife Sciences AG subsidiaries and ownership
Company hierarchySubsidiaries19 records
Xlife Sciences AG funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xlife Sciences AG M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xlife Sciences AG
What does Xlife Sciences AG do?
Xlife Sciences AG operates as a Swiss life sciences investment holding company that identifies, develops, and commercializes early-stage research projects sourced from universities and research institutions. The company builds and manages a portfolio of companies across four segments (Technology Platforms, Biotechnologies/Therapeutics, Medical Technology, and Artificial Intelligence) from inception through proof-of-concept, exiting via trade sales, licensing, or IPOs. VERAXA Biotech's NASDAQ listing in June 2026, with a market capitalization exceeding USD 500 million, exemplifies the platform's incubation-to-exit model.
Is Xlife Sciences AG a public or private company?
Xlife Sciences AG is a public company. It is classified as public and is currently operating.
When was Xlife Sciences AG founded?
Xlife Sciences AG was founded in 2019. It employs 11 to 50 people.
Where is Xlife Sciences AG based?
Xlife Sciences AG is headquartered in Zürich, Switzerland, in the Europe region.
How does Xlife Sciences AG make money?
Three revenue lines are on record. Portfolio Company Exits are the primary driver. The others are portfolio Company Services and revenue from Portfolio Operations.
Who are Xlife Sciences AG's main competitors?
Direct peers on record are PureTech Health, BB Biotech AG, HBM Healthcare Investments, TVM Capital Life Sciences, EQT Life Sciences (formerly LSP) and Vesalius Biocapital. Broad incumbents are Index Ventures (Life Sciences) and OrbiMed Advisors. Emerging players are Roche Venture Fund and Novartis Venture Fund.
Does Xlife Sciences AG have an API?
No public API is recorded for Xlife Sciences AG.
What industry is Xlife Sciences AG in?
Xlife Sciences AG's product category is Life Sciences Investment & Incubation. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 523940 and its SIC code is 6282.